OVID - Ovid Therapeutics Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Ovid Therapeutics Inc.

1460 Broadway
Suite 15044
New York, NY 10036
United States
646-661-7661
http://www.ovidrx.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees53

Key Executives

NameTitlePayExercisedYear Born
Dr. Jeremy Max LevinChairman & CEO754.15kN/A1953
Dr. Matthew J. DuringFounder & Chairman of Scientific Advisory Board669.93kN/A1957
Dr. Amit RakhitChief Medical Officer and Head of R&D668.71kN/A1970
Ms. Lora PikeSr. Director of Investor Relations & PRN/AN/AN/A
Mr. Thomas Michael PeroneSr. VP, Gen. Counsel & Sec.N/AN/A1965
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome. It is also developing OV935, a drug candidate, which has completed Phase 1b/2a trial for rare epileptic encephalopathies. The company has collaboration agreement with Takeda Pharmaceutical Company Limited; and a license agreement with H. Lundbeck A/S. Ovid Therapeutics Inc. was founded in 2014 and is headquartered in New York, New York.

Corporate Governance

Ovid Therapeutics Inc.’s ISS Governance QualityScore as of June 25, 2019 is 9. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.